PD-1 and PD-L1 Inhibitors Market By Type (PD-1 (Pembrolizumab, Nivolumab, Etc.), PD-L1 (Atezolizumab, Avelumab, Etc.)); By Application (Non-small Cell Lung Cancer (NSCLC), Urothelial Carcinoma (UC), Esophageal Cancer, Melanoma, Head and Neck Cancer, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
PD-1 inhibitors and PD-L1 inhibitors are a class of anticancer medications that disrupt the action of PD-1 and PDL1 immune checkpoint proteins found on the surface of cells. Immune checkpoint inhibitors are becoming a front-line treatment for a variety of cancers. The immune system's ability to distinguish between normal and "foreign" cells in the body is a crucial function. This allows the immune system to attack unwanted cells while leaving healthy cells alone. Immune checkpoints are molecules on specific immune cells that must be activated or deactivated in order to initiate an immune response. Immunotherapy has dramatically altered the therapeutic landscapes of clinical oncology over the last decade. Several monoclonal antibodies (mAbs) targeting immune checkpoints, such as PD-1 and PD-L1, have been added to the therapeutic arsenal of several cancers, including non-small cell lung cancer (NSCLC), melanoma, and squamous head and neck cancer amongst others. The high prevalence of cancer is a critical factor contributing towards the increase of PD-1 and PD-L1 inhibitors market. Moreover, the technological advancements and innovations in the sector is anticipated to fuel the market growth over the period of next eight years.
Recently, a lot of attention has been devoted to the development of peptide-based inhibitors and nonpeptidic small molecules that target PD1/PDL1. Small molecules can also be created by structurally modifying peptidomimetic inhibitors. Small-molecule drugs have significant advantages over monoclonal antibodies. The first inhibitor, AUNP-12, is a 29-amino acid branching peptide that was reportedly patented in 2014. AUNP-12 effectively inhibited tumor cell growth and metastasis in an animal study with few adverse effects. Additionally, the key factors driving the growth of the PD-1 and PD-L1 inhibitors market are an increase in the incidence of various types of cancer, favorable reimbursement policies, and increased research and development activities undertaken by the major players, as well as a surge in the adoption of immune checkpoint inhibitor drugs. The high cost of checkpoint inhibitors, on the other hand, may limit the market growth.
Since early March 2020, the world has been in the grip of a COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). COVID-19 causes a wide range of signs and symptoms, ranging from mild illness to acute pneumonia. In the early stages, the overall impact of COVID-19 on the PD-1 inhibitors and PD-L1 inhibitors market remained negative, owing to a decrease in the number of cancer patients visiting hospitals and clinics for immune checkpoint inhibitor therapy (ICI), which led to a decrease in the demand for checkpoint inhibitors products. For example, according to NCBI, in 2020, overall cancer therapies were reduced by 50% during COVID-19. However, in the second half of 2020, understanding the link between patients' immune features and disease severity was a critical step in the fight against this pandemic. Immune checkpoint molecules, such as PD-1 and PD-L1, play an important role as modulators in innate and especially adaptive immune responses. Among the checkpoint molecules, the PD-1/PD-L1 axis exhibited a significant role in maintaining the delicate balance between immune response and immune-mediated cellular damage during inflammation. Furthermore, increased investments towards checkpoint inhibitor innovation showcases potential growth opportunities for the major players in the PD-1 and PD-L1 inhibitors market over the forecast period.
In terms of revenue, PD-1 and PD-L1 inhibitors market was valued at US$ 28,497.82 Mn in 2020 growing at a CAGR of 18.8% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global PD-1 and PD-L1 Inhibitors Market Revenue & Forecast, (US$ Million), 2015 – 2029
Type Outlook:
Based on type, the global PD-1 and PD-L1 inhibitors market has been primarily segmented into PD-1 (pembrolizumab, nivolumab, etc.) and PD-L1 (atezolizumab, avelumab, etc.). The PD-1 segment is reported to witness the highest market share over the forecast period. The increased volume of research activities, approvals, and prescriptions for drugs like nivolumab and pembrolizumab are contributing towards the segment's growth. For instance, Novartis announced in September 2021 that the FDA had accepted the biologics licence application (BLA) for the anti-pd-1 immune checkpoint inhibitor tislelizumab for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in people who had previously received systemic therapy. Tislelizumab is a humanised IGG4 ANTI-PD-1 monoclonal antibody that is being studied as a monotherapy as well as in combination with other treatments.
Application Outlook:
Based on application, the global PD-1 and PD-L1 inhibitors market has been classified into non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), esophageal cancer, melanoma, head and neck cancer, and others. Non-small cell lung cancer (NSCLC) is accounted for a significant share of the market and is expected to be the fastest growing segment over the forecast period due to an increase in drug approvals for the treatment of various solid tumors in the previous years.
Region Outlook:
Asia Pacific in the global PD-1 and PD-L1 inhibitors market is expected to be the fastest growing region over the forecast period. The increasing prevalence of cancer diseases, increasing need for safer cancer therapies, and the growing number of FDA approvals, are all factors contributing towards the growth of the market in the region. Furthermore, favorable support in the form of investments from both, private and public sector towards research and development activities is anticipated to aid the region’s growth in the global market over the forecast period.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of PD-1 and PD-L1 inhibitors market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
The key market participants operating in the global PD-1 and PD-L1 inhibitors market are:
- Amgen Inc.
- AstraZeneca
- Bristol‑Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi
- Other Market Participants
Global PD-1 and PD-L1 Inhibitors Market:
- By Type
- PD-1 (Pembrolizumab, Nivolumab, Etc.)
- PD-L1 (Atezolizumab, Avelumab, Etc.)
- By Application
- Non-small Cell Lung Cancer (NSCLC)
- Urothelial Carcinoma (UC)
- Esophageal Cancer
- Melanoma
- Head and Neck Cancer
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of PD-1 and PD-L1 Inhibitors Market
6. Market Synopsis: PD-1
and PD-L1 Inhibitors Market
7. PD-1 and PD-L1 Inhibitors Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
PD-1 and PD-L1 Inhibitors Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: PD-1 and PD-L1 Inhibitors Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on PD-1 and PD-L1 Inhibitors Market
8. Global PD-1 and PD-L1 Inhibitors Market Analysis and
Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global
PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
8.2. Global
PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. PD-1
(Pembrolizumab, Nivolumab, Etc.)
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2020
8.2.1.3. Market Forecast, 2021 - 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2020
8.2.1.5.1.2. Market
Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2020
8.2.1.5.2.2. Market
Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2020
8.2.1.5.3.2. Market
Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2020
8.2.1.5.4.2. Market
Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2020
8.2.1.5.5.2. Market
Forecast, 2021 - 2029
8.2.2. PD-L1
(Atezolizumab, Avelumab, Etc.)
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2020
8.2.2.5.1.2. Market
Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2020
8.2.2.5.2.2. Market
Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2020
8.2.2.5.3.2. Market
Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2020
8.2.2.5.4.2. Market
Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2020
8.2.2.5.5.2. Market
Forecast, 2021 - 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global PD-1 and PD-L1 Inhibitors Market Analysis and
Forecasts, 2021 – 2029
9.1. Overview
9.2. Global
PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1. Non-small
Cell Lung Cancer (NSCLC)
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2020
9.2.1.3. Market Forecast, 2021 - 2029
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2020
9.2.1.5.1.2. Market
Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2020
9.2.1.5.2.2. Market
Forecast, 2021 - 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2020
9.2.1.5.3.2. Market
Forecast, 2021 - 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2020
9.2.1.5.4.2. Market
Forecast, 2021 - 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2020
9.2.1.5.5.2. Market
Forecast, 2021 - 2029
9.2.2. Urothelial
Carcinoma (UC)
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2020
9.2.2.5.1.2. Market
Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2020
9.2.2.5.2.2. Market
Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2020
9.2.2.5.3.2. Market
Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2020
9.2.2.5.4.2. Market
Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2020
9.2.2.5.5.2. Market
Forecast, 2021 - 2029
9.2.3. Esophageal
Cancer
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2020
9.2.3.3. Market Forecast, 2021 - 2029
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2020
9.2.3.5.1.2. Market
Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2020
9.2.3.5.2.2. Market
Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2020
9.2.3.5.3.2. Market
Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2020
9.2.3.5.4.2. Market
Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2020
9.2.3.5.5.2. Market
Forecast, 2021 - 2029
9.2.4. Melanoma
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2020
9.2.4.3. Market Forecast, 2021 - 2029
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2020
9.2.4.5.1.2. Market
Forecast, 2021 - 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2020
9.2.4.5.2.2. Market
Forecast, 2021 - 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2020
9.2.4.5.3.2. Market
Forecast, 2021 - 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2020
9.2.4.5.4.2. Market
Forecast, 2021 - 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2020
9.2.4.5.5.2. Market
Forecast, 2021 - 2029
9.2.5. Head and
Neck Cancer
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2020
9.2.5.3. Market Forecast, 2021 - 2029
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2020
9.2.5.5.1.2. Market
Forecast, 2021 - 2029
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2020
9.2.5.5.2.2. Market
Forecast, 2021 - 2029
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2020
9.2.5.5.3.2. Market
Forecast, 2021 - 2029
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2020
9.2.5.5.4.2. Market
Forecast, 2021 - 2029
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2020
9.2.5.5.5.2. Market
Forecast, 2021 - 2029
9.2.6. Others
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2015 - 2020
9.2.6.3. Market Forecast, 2021 - 2029
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market
Estimation, 2015 - 2020
9.2.6.5.1.2. Market
Forecast, 2021 - 2029
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 - 2020
9.2.6.5.2.2. Market
Forecast, 2021 - 2029
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market
Estimation, 2015 - 2020
9.2.6.5.3.2. Market
Forecast, 2021 - 2029
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 - 2020
9.2.6.5.4.2. Market
Forecast, 2021 - 2029
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market
Estimation, 2015 - 2020
9.2.6.5.5.2. Market
Forecast, 2021 - 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application
10. North America PD-1 and PD-L1 Inhibitors Market Analysis and
Forecasts, 2021 - 2029
10.1. Overview
10.1.1. North
America PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
10.2. North
America PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Type
10.2.1. PD-1
(Pembrolizumab, Nivolumab, Etc.)
10.2.2. PD-L1
(Atezolizumab, Avelumab, Etc.)
10.3. North
America PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Application
10.3.1. Non-small
Cell Lung Cancer (NSCLC)
10.3.2. Urothelial
Carcinoma (UC)
10.3.3. Esophageal
Cancer
10.3.4. Melanoma
10.3.5. Head
and Neck Cancer
10.3.6. Others
10.4. North
America PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Country
10.4.1. U.S
10.4.1.1. U.S PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
10.4.1.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
10.4.1.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
10.4.1.2. U.S PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
10.4.1.2.1. Non-small Cell Lung Cancer (NSCLC)
10.4.1.2.2. Urothelial Carcinoma (UC)
10.4.1.2.3. Esophageal Cancer
10.4.1.2.4. Melanoma
10.4.1.2.5. Head and Neck Cancer
10.4.1.2.6. Others
10.4.2. Canada
10.4.2.1. Canada PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
10.4.2.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
10.4.2.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
10.4.2.2. Canada PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
10.4.2.2.1. Non-small Cell Lung Cancer (NSCLC)
10.4.2.2.2. Urothelial Carcinoma (UC)
10.4.2.2.3. Esophageal Cancer
10.4.2.2.4. Melanoma
10.4.2.2.5. Head and Neck Cancer
10.4.2.2.6. Others
10.4.3. Mexico
10.4.3.1. Mexico PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
10.4.3.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
10.4.3.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
10.4.3.2. Mexico PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
10.4.3.2.1. Non-small Cell Lung Cancer (NSCLC)
10.4.3.2.2. Urothelial Carcinoma (UC)
10.4.3.2.3. Esophageal Cancer
10.4.3.2.4. Melanoma
10.4.3.2.5. Head and Neck Cancer
10.4.3.2.6. Others
10.4.4. Rest of
North America
10.4.4.1. Rest of North America PD-1 and PD-L1 Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Type
10.4.4.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
10.4.4.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
10.4.4.2. Rest of North America PD-1 and PD-L1 Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Application
10.4.4.2.1. Non-small Cell Lung Cancer (NSCLC)
10.4.4.2.2. Urothelial Carcinoma (UC)
10.4.4.2.3. Esophageal Cancer
10.4.4.2.4. Melanoma
10.4.4.2.5. Head and Neck Cancer
10.4.4.2.6. Others
10.5. Key
Segment for Channeling Investments
10.5.1. By
Country
10.5.2. By Type
10.5.3. By
Application
11. Europe PD-1 and PD-L1 Inhibitors Market Analysis and
Forecasts, 2021 - 2029
11.1. Overview
11.1.1. Europe
PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
11.2. Europe
PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By Type
11.2.1. PD-1
(Pembrolizumab, Nivolumab, Etc.)
11.2.2. PD-L1
(Atezolizumab, Avelumab, Etc.)
11.3. Europe
PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By Application
11.3.1. Non-small
Cell Lung Cancer (NSCLC)
11.3.2. Urothelial
Carcinoma (UC)
11.3.3. Esophageal
Cancer
11.3.4. Melanoma
11.3.5. Head
and Neck Cancer
11.3.6. Others
11.4. Europe
PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By Country
11.4.1. France
11.4.1.1. France PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
11.4.1.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
11.4.1.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
11.4.1.2. France PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
11.4.1.2.1. Non-small Cell Lung Cancer (NSCLC)
11.4.1.2.2. Urothelial Carcinoma (UC)
11.4.1.2.3. Esophageal Cancer
11.4.1.2.4. Melanoma
11.4.1.2.5. Head and Neck Cancer
11.4.1.2.6. Others
11.4.2. The UK
11.4.2.1. The UK PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
11.4.2.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
11.4.2.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
11.4.2.2. The UK PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
11.4.2.2.1. Non-small Cell Lung Cancer (NSCLC)
11.4.2.2.2. Urothelial Carcinoma (UC)
11.4.2.2.3. Esophageal Cancer
11.4.2.2.4. Melanoma
11.4.2.2.5. Head and Neck Cancer
11.4.2.2.6. Others
11.4.3. Spain
11.4.3.1. Spain PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
11.4.3.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
11.4.3.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
11.4.3.2. Spain PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
11.4.3.2.1. Non-small Cell Lung Cancer (NSCLC)
11.4.3.2.2. Urothelial Carcinoma (UC)
11.4.3.2.3. Esophageal Cancer
11.4.3.2.4. Melanoma
11.4.3.2.5. Head and Neck Cancer
11.4.3.2.6. Others
11.4.4. Germany
11.4.4.1. Germany PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
11.4.4.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
11.4.4.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
11.4.4.2. Germany PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
11.4.4.2.1. Non-small Cell Lung Cancer (NSCLC)
11.4.4.2.2. Urothelial Carcinoma (UC)
11.4.4.2.3. Esophageal Cancer
11.4.4.2.4. Melanoma
11.4.4.2.5. Head and Neck Cancer
11.4.4.2.6. Others
11.4.5. Italy
11.4.5.1. Italy PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
11.4.5.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
11.4.5.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
11.4.5.2. Italy PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
11.4.5.2.1. Non-small Cell Lung Cancer (NSCLC)
11.4.5.2.2. Urothelial Carcinoma (UC)
11.4.5.2.3. Esophageal Cancer
11.4.5.2.4. Melanoma
11.4.5.2.5. Head and Neck Cancer
11.4.5.2.6. Others
11.4.6. Nordic
Countries
11.4.6.1. Nordic Countries PD-1 and PD-L1 Inhibitors Market Revenue (US$
Mn) and Forecasts, By Type
11.4.6.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
11.4.6.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
11.4.6.2. Nordic Countries PD-1 and PD-L1 Inhibitors Market Revenue (US$
Mn) and Forecasts, By Application
11.4.6.2.1. Non-small Cell Lung Cancer (NSCLC)
11.4.6.2.2. Urothelial Carcinoma (UC)
11.4.6.2.3. Esophageal Cancer
11.4.6.2.4. Melanoma
11.4.6.2.5. Head and Neck Cancer
11.4.6.2.6. Others
11.4.6.3. Nordic Countries PD-1 and PD-L1 Inhibitors Market Revenue (US$
Mn) and Forecasts, By Country
11.4.6.3.1. Denmark
11.4.6.3.2. Finland
11.4.6.3.3. Iceland
11.4.6.3.4. Sweden
11.4.6.3.5. Norway
11.4.7. Benelux
Union
11.4.7.1. Benelux Union PD-1 and PD-L1 Inhibitors Market Revenue (US$
Mn) and Forecasts, By Type
11.4.7.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
11.4.7.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
11.4.7.2. Benelux Union PD-1 and PD-L1 Inhibitors Market Revenue (US$
Mn) and Forecasts, By Application
11.4.7.2.1. Non-small Cell Lung Cancer (NSCLC)
11.4.7.2.2. Urothelial Carcinoma (UC)
11.4.7.2.3. Esophageal Cancer
11.4.7.2.4. Melanoma
11.4.7.2.5. Head and Neck Cancer
11.4.7.2.6. Others
11.4.7.3. Benelux Union PD-1 and PD-L1 Inhibitors Market Revenue (US$
Mn) and Forecasts, By Country
11.4.7.3.1. Belgium
11.4.7.3.2. The Netherlands
11.4.7.3.3. Luxembourg
11.4.8. Rest of
Europe
11.4.8.1. Rest of Europe PD-1 and PD-L1 Inhibitors Market Revenue (US$
Mn) and Forecasts, By Type
11.4.8.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
11.4.8.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
11.4.8.2. Rest of Europe PD-1 and PD-L1 Inhibitors Market Revenue (US$
Mn) and Forecasts, By Application
11.4.8.2.1. Non-small Cell Lung Cancer (NSCLC)
11.4.8.2.2. Urothelial Carcinoma (UC)
11.4.8.2.3. Esophageal Cancer
11.4.8.2.4. Melanoma
11.4.8.2.5. Head and Neck Cancer
11.4.8.2.6. Others
11.5. Key
Segment for Channeling Investments
11.5.1. By Country
11.5.2. By Type
11.5.3. By
Application
12. Asia Pacific PD-1 and PD-L1 Inhibitors Market Analysis and
Forecasts, 2021 - 2029
12.1. Overview
12.1.1. Asia
Pacific PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
12.2. Asia
Pacific PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Type
12.2.1. PD-1
(Pembrolizumab, Nivolumab, Etc.)
12.2.2. PD-L1
(Atezolizumab, Avelumab, Etc.)
12.3. Asia
Pacific PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Application
12.3.1. Non-small
Cell Lung Cancer (NSCLC)
12.3.2. Urothelial
Carcinoma (UC)
12.3.3. Esophageal
Cancer
12.3.4. Melanoma
12.3.5. Head
and Neck Cancer
12.3.6. Others
12.4. Asia
Pacific PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Country
12.4.1. China
12.4.1.1. China PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
12.4.1.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
12.4.1.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
12.4.1.2. China PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
12.4.1.2.1. Non-small Cell Lung Cancer (NSCLC)
12.4.1.2.2. Urothelial Carcinoma (UC)
12.4.1.2.3. Esophageal Cancer
12.4.1.2.4. Melanoma
12.4.1.2.5. Head and Neck Cancer
12.4.1.2.6. Others
12.4.2. Japan
12.4.2.1. Japan PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
12.4.2.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
12.4.2.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
12.4.2.2. Japan PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
12.4.2.2.1. Non-small Cell Lung Cancer (NSCLC)
12.4.2.2.2. Urothelial Carcinoma (UC)
12.4.2.2.3. Esophageal Cancer
12.4.2.2.4. Melanoma
12.4.2.2.5. Head and Neck Cancer
12.4.2.2.6. Others
12.4.3. India
12.4.3.1. India PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
12.4.3.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
12.4.3.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
12.4.3.2. India PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
12.4.3.2.1. Non-small Cell Lung Cancer (NSCLC)
12.4.3.2.2. Urothelial Carcinoma (UC)
12.4.3.2.3. Esophageal Cancer
12.4.3.2.4. Melanoma
12.4.3.2.5. Head and Neck Cancer
12.4.3.2.6. Others
12.4.4. New
Zealand
12.4.4.1. New Zealand PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Type
12.4.4.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
12.4.4.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
12.4.4.2. New Zealand PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Application
12.4.4.2.1. Non-small Cell Lung Cancer (NSCLC)
12.4.4.2.2. Urothelial Carcinoma (UC)
12.4.4.2.3. Esophageal Cancer
12.4.4.2.4. Melanoma
12.4.4.2.5. Head and Neck Cancer
12.4.4.2.6. Others
12.4.5. Australia
12.4.5.1. Australia PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Type
12.4.5.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
12.4.5.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
12.4.5.2. Australia PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Application
12.4.5.2.1. Non-small Cell Lung Cancer (NSCLC)
12.4.5.2.2. Urothelial Carcinoma (UC)
12.4.5.2.3. Esophageal Cancer
12.4.5.2.4. Melanoma
12.4.5.2.5. Head and Neck Cancer
12.4.5.2.6. Others
12.4.6. South
Korea
12.4.6.1. South Korea PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Type
12.4.6.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
12.4.6.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
12.4.6.2. South Korea PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Application
12.4.6.2.1. Non-small Cell Lung Cancer (NSCLC)
12.4.6.2.2. Urothelial Carcinoma (UC)
12.4.6.2.3. Esophageal Cancer
12.4.6.2.4. Melanoma
12.4.6.2.5. Head and Neck Cancer
12.4.6.2.6. Others
12.4.7. Southeast
Asia
12.4.7.1. Southeast Asia PD-1 and PD-L1 Inhibitors Market Revenue (US$
Mn) and Forecasts, By Type
12.4.7.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
12.4.7.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
12.4.7.2. Southeast Asia PD-1 and PD-L1 Inhibitors Market Revenue (US$
Mn) and Forecasts, By Application
12.4.7.2.1. Non-small Cell Lung Cancer (NSCLC)
12.4.7.2.2. Urothelial Carcinoma (UC)
12.4.7.2.3. Esophageal Cancer
12.4.7.2.4. Melanoma
12.4.7.2.5. Head and Neck Cancer
12.4.7.2.6. Others
12.4.7.3. Southeast Asia PD-1 and PD-L1 Inhibitors Market Revenue (US$
Mn) and Forecasts, By Country
12.4.7.3.1. Indonesia
12.4.7.3.2. Thailand
12.4.7.3.3. Malaysia
12.4.7.3.4. Singapore
12.4.7.3.5. Rest of Southeast Asia
12.4.8. Rest of
Asia Pacific
12.4.8.1. Rest of Asia Pacific PD-1 and PD-L1 Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Type
12.4.8.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
12.4.8.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
12.4.8.2. Rest of Asia Pacific PD-1 and PD-L1 Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Application
12.4.8.2.1. Non-small Cell Lung Cancer (NSCLC)
12.4.8.2.2. Urothelial Carcinoma (UC)
12.4.8.2.3. Esophageal Cancer
12.4.8.2.4. Melanoma
12.4.8.2.5. Head and Neck Cancer
12.4.8.2.6. Others
12.5. Key
Segment for Channeling Investments
12.5.1. By
Country
12.5.2. By Type
12.5.3. By
Application
13. Middle East and Africa PD-1 and PD-L1 Inhibitors Market
Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Middle
East and Africa PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
13.2. Middle
East and Africa PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
13.2.1. PD-1
(Pembrolizumab, Nivolumab, Etc.)
13.2.2. PD-L1
(Atezolizumab, Avelumab, Etc.)
13.3. Middle
East and Africa PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
13.3.1. Non-small
Cell Lung Cancer (NSCLC)
13.3.2. Urothelial
Carcinoma (UC)
13.3.3. Esophageal
Cancer
13.3.4. Melanoma
13.3.5. Head
and Neck Cancer
13.3.6. Others
13.4. Middle
East and Africa PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Country
13.4.1. Saudi
Arabia
13.4.1.1. Saudi Arabia PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Type
13.4.1.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
13.4.1.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
13.4.1.2. Saudi Arabia PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Application
13.4.1.2.1. Non-small Cell Lung Cancer (NSCLC)
13.4.1.2.2. Urothelial Carcinoma (UC)
13.4.1.2.3. Esophageal Cancer
13.4.1.2.4. Melanoma
13.4.1.2.5. Head and Neck Cancer
13.4.1.2.6. Others
13.4.2. UAE
13.4.2.1. UAE PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
13.4.2.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
13.4.2.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
13.4.2.2. UAE PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
13.4.2.2.1. Non-small Cell Lung Cancer (NSCLC)
13.4.2.2.2. Urothelial Carcinoma (UC)
13.4.2.2.3. Esophageal Cancer
13.4.2.2.4. Melanoma
13.4.2.2.5. Head and Neck Cancer
13.4.2.2.6. Others
13.4.3. Egypt
13.4.3.1. Egypt PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
13.4.3.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
13.4.3.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
13.4.3.2. Egypt PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
13.4.3.2.1. Non-small Cell Lung Cancer (NSCLC)
13.4.3.2.2. Urothelial Carcinoma (UC)
13.4.3.2.3. Esophageal Cancer
13.4.3.2.4. Melanoma
13.4.3.2.5. Head and Neck Cancer
13.4.3.2.6. Others
13.4.4. Kuwait
13.4.4.1. Kuwait PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
13.4.4.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
13.4.4.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
13.4.4.2. Kuwait PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
13.4.4.2.1. Non-small Cell Lung Cancer (NSCLC)
13.4.4.2.2. Urothelial Carcinoma (UC)
13.4.4.2.3. Esophageal Cancer
13.4.4.2.4. Melanoma
13.4.4.2.5. Head and Neck Cancer
13.4.4.2.6. Others
13.4.5. South
Africa
13.4.5.1. South Africa PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Type
13.4.5.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
13.4.5.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
13.4.5.2. South Africa PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Application
13.4.5.2.1. Non-small Cell Lung Cancer (NSCLC)
13.4.5.2.2. Urothelial Carcinoma (UC)
13.4.5.2.3. Esophageal Cancer
13.4.5.2.4. Melanoma
13.4.5.2.5. Head and Neck Cancer
13.4.5.2.6. Others
13.4.6. Rest of
Middle East & Africa
13.4.6.1. Rest of Middle East & Africa PD-1 and PD-L1 Inhibitors
Market Revenue (US$ Mn) and Forecasts, By Type
13.4.6.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
13.4.6.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
13.4.6.2. Rest of Middle East & Africa PD-1 and PD-L1 Inhibitors
Market Revenue (US$ Mn) and Forecasts, By Application
13.4.6.2.1. Non-small Cell Lung Cancer (NSCLC)
13.4.6.2.2. Urothelial Carcinoma (UC)
13.4.6.2.3. Esophageal Cancer
13.4.6.2.4. Melanoma
13.4.6.2.5. Head and Neck Cancer
13.4.6.2.6. Others
13.5. Key
Segment for Channeling Investments
13.5.1. By
Country
13.5.2. By Type
13.5.3. By
Application
14. Latin America PD-1 and PD-L1 Inhibitors Market Analysis and
Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Latin
America PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
14.2. Latin
America PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Type
14.2.1. PD-1
(Pembrolizumab, Nivolumab, Etc.)
14.2.2. PD-L1
(Atezolizumab, Avelumab, Etc.)
14.3. Latin
America PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Application
14.3.1. Non-small
Cell Lung Cancer (NSCLC)
14.3.2. Urothelial
Carcinoma (UC)
14.3.3. Esophageal
Cancer
14.3.4. Melanoma
14.3.5. Head
and Neck Cancer
14.3.6. Others
14.4. Latin
America PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Country
14.4.1. Brazil
14.4.1.1. Brazil PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Type
14.4.1.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
14.4.1.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
14.4.1.2. Brazil PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Application
14.4.1.2.1. Non-small Cell Lung Cancer (NSCLC)
14.4.1.2.2. Urothelial Carcinoma (UC)
14.4.1.2.3. Esophageal Cancer
14.4.1.2.4. Melanoma
14.4.1.2.5. Head and Neck Cancer
14.4.1.2.6. Others
14.4.2. Argentina
14.4.2.1. Argentina PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Type
14.4.2.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
14.4.2.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
14.4.2.2. Argentina PD-1 and PD-L1 Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Application
14.4.2.2.1. Non-small Cell Lung Cancer (NSCLC)
14.4.2.2.2. Urothelial Carcinoma (UC)
14.4.2.2.3. Esophageal Cancer
14.4.2.2.4. Melanoma
14.4.2.2.5. Head and Neck Cancer
14.4.2.2.6. Others
14.4.3. Rest of
Latin America
14.4.3.1. Rest of Latin America PD-1 and PD-L1 Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Type
14.4.3.1.1. PD-1 (Pembrolizumab, Nivolumab, Etc.)
14.4.3.1.2. PD-L1 (Atezolizumab, Avelumab, Etc.)
14.4.3.2. Rest of Latin America PD-1 and PD-L1 Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Application
14.4.3.2.1. Non-small Cell Lung Cancer (NSCLC)
14.4.3.2.2. Urothelial Carcinoma (UC)
14.4.3.2.3. Esophageal Cancer
14.4.3.2.4. Melanoma
14.4.3.2.5. Head and Neck Cancer
14.4.3.2.6. Others
14.5. Key
Segment for Channeling Investments
14.5.1. By
Country
14.5.2. By Type
14.5.3. By
Application
15. Competitive Benchmarking
15.1. Market
Share Analysis, 2020
15.2. Global
Presence and Growth Strategies
15.2.1. Mergers
and Acquisitions
15.2.2. Product
Launches
15.2.3. Investments
Trends
15.2.4. R&D
Initiatives
16. Player Profiles
16.1. Amgen
Inc.
16.1.1. Company
Details
16.1.2. Company
Overview
16.1.3. Product
Offerings
16.1.4. Key
Developments
16.1.5. Financial
Analysis
16.1.6. SWOT
Analysis
16.1.7. Business
Strategies
16.2. AstraZeneca
16.2.1. Company
Details
16.2.2. Company
Overview
16.2.3. Product
Offerings
16.2.4. Key
Developments
16.2.5. Financial
Analysis
16.2.6. SWOT
Analysis
16.2.7. Business Strategies
16.3. Bristol‑Myers
Squibb Company
16.3.1. Company
Details
16.3.2. Company
Overview
16.3.3. Product
Offerings
16.3.4. Key
Developments
16.3.5. Financial
Analysis
16.3.6. SWOT Analysis
16.3.7. Business
Strategies
16.4. F. Hoffmann-La Roche Ltd
16.4.1. Company
Details
16.4.2. Company
Overview
16.4.3. Product
Offerings
16.4.4. Key
Developments
16.4.5. Financial
Analysis
16.4.6. SWOT
Analysis
16.4.7. Business
Strategies
16.5. Gilead Sciences, Inc.
16.5.1. Company
Details
16.5.2. Company
Overview
16.5.3. Product
Offerings
16.5.4. Key
Developments
16.5.5. Financial
Analysis
16.5.6. SWOT
Analysis
16.5.7. Business
Strategies
16.6. Merck & Co., Inc.
16.6.1. Company
Details
16.6.2. Company
Overview
16.6.3. Product
Offerings
16.6.4. Key
Developments
16.6.5. Financial
Analysis
16.6.6. SWOT
Analysis
16.6.7. Business
Strategies
16.7. Novartis AG
16.7.1. Company
Details
16.7.2. Company
Overview
16.7.3. Product
Offerings
16.7.4. Key
Developments
16.7.5. Financial
Analysis
16.7.6. SWOT
Analysis
16.7.7. Business
Strategies
16.8. Pfizer Inc.
16.8.1. Company
Details
16.8.2. Company
Overview
16.8.3. Product
Offerings
16.8.4. Key
Developments
16.8.5. Financial
Analysis
16.8.6. SWOT
Analysis
16.8.7. Business
Strategies
16.9. Regeneron Pharmaceuticals Inc.
16.9.1. Company
Details
16.9.2. Company
Overview
16.9.3. Product
Offerings
16.9.4. Key
Developments
16.9.5. Financial
Analysis
16.9.6. SWOT
Analysis
16.9.7. Business
Strategies
16.10. Sanofi
16.10.1. Company
Details
16.10.2. Company
Overview
16.10.3. Product
Offerings
16.10.4. Key
Developments
16.10.5. Financial
Analysis
16.10.6. SWOT
Analysis
16.10.7. Business
Strategies
16.11. Other Market Participants
17. Key Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.